How to Get Farxiga (Dapagliflozin) in Indiana

Indiana Allows Telehealth Prescribing for Farxiga

Residents across Indiana can receive a dapagliflozin prescription through telehealth without an initial in-person visit. Indiana's telehealth parity laws permit licensed prescribers to evaluate patients via synchronous audio-video encounters and issue prescriptions for non-controlled medications, which includes SGLT2 inhibitors like Farxiga.

This matters for patients in rural counties. Indiana has 92 counties, and many lack an endocrinologist or cardiologist within 30 miles. Telehealth platforms staffed by board-certified internists or endocrinologists can evaluate a patient's metabolic history, review uploaded lab work, and transmit an electronic prescription to any Indiana-licensed pharmacy the same day.

The prescriber must hold an active Indiana medical license or be registered through the Interstate Medical Licensure Compact. Indiana joined the Compact in 2017, expanding the pool of out-of-state physicians who can legally treat Indiana residents remotely. Nurse practitioners in Indiana operate under a collaborative practice agreement with a physician, and they can prescribe Farxiga within that scope 1.

A typical telehealth Farxiga consultation takes 15 to 25 minutes. The clinician will confirm the diagnosis (type 2 diabetes, heart failure with reduced ejection fraction, or CKD), review contraindications like recurrent genital mycotic infections or severe renal impairment (eGFR <25 mL/min/1.73 m² for the diabetes indication), and verify that baseline labs are current within 90 days.

Required Labs Before Starting Farxiga in Indiana

Every prescriber, whether in-person or telehealth, will need a recent metabolic panel before writing a Farxiga prescription. The baseline laboratory requirements are straightforward but non-negotiable.

At minimum, expect orders for a basic metabolic panel (BMP) including serum creatinine and estimated glomerular filtration rate (eGFR), hemoglobin A1c if the indication is type 2 diabetes, fasting lipid panel, urinalysis with urine albumin-to-creatinine ratio (UACR), and a complete blood count. The eGFR value determines both eligibility and dosing. For the type 2 diabetes indication, the FDA label recommends against initiation when eGFR falls below 25 mL/min/1.73 m². For heart failure, no eGFR floor exists per the DAPA-HF trial protocol [2].

Indiana has over 400 Quest Diagnostics and Labcorp draw sites. Most telehealth platforms partner with one or both networks, and patients can walk into any partnered location without an appointment. Results typically post within 24 to 48 hours. Patients in Indianapolis, Fort Wayne, Evansville, and South Bend will find multiple draw sites within a 10-minute drive. Rural patients near Jasper or Tell City may need to drive 20 to 40 minutes.

"Baseline eGFR and UACR are the two values that drive every prescribing decision for an SGLT2 inhibitor. Without them, we cannot safely initiate therapy or select the right indication for prior authorization." This reflects the standard clinical workflow described in the 2022 ADA Standards of Care 3.

Indiana Medicaid Does Not Cover Farxiga for Type 2 Diabetes Alone

This is the single biggest access barrier for low-income Indiana patients. Indiana Medicaid, administered through managed care organizations like Anthem, CareSource, MDwise, and MHS, does not include Farxiga on its preferred drug list for the type 2 diabetes indication as a standalone diagnosis.

That restriction does not mean Medicaid patients have zero options. Patients with a concurrent diagnosis of heart failure with reduced ejection fraction (HFrEF) or chronic kidney disease (CKD stages 2 through 4) may qualify for coverage under those indications. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001) compared to placebo, regardless of diabetes status 2. That evidence base is what moved payers to cover the cardiac and renal indications more readily than diabetes alone.

For patients who carry only a type 2 diabetes diagnosis and are on Indiana Medicaid, the following workarounds exist. AstraZeneca's Farxiga Savings Program can reduce the out-of-pocket cost to as low as $0 per month for commercially insured patients, though Medicaid enrollees are excluded from manufacturer copay cards by federal anti-kickback statutes. The AstraZeneca Patient Assistance Program (AZ&Me) provides free medication to uninsured or underinsured patients with household incomes below 400% of the federal poverty level. Application requires proof of income, a valid prescription, and a signed prescriber attestation form.

Indiana patients on the Healthy Indiana Plan (HIP) 2.0 face similar formulary restrictions. HIP Basic and HIP Plus both route pharmacy benefits through the same MCO formularies. A formal exception request from the prescriber, citing clinical necessity and prior failure of preferred agents (typically metformin and a sulfonylurea), may succeed but approval rates vary by MCO.

Prior Authorization: What Indiana Insurers Require

Nearly every Indiana commercial plan and all Medicaid MCOs require prior authorization before dispensing Farxiga. The documentation burden falls on the prescribing clinician, but patients benefit from understanding what the insurer needs.

A standard prior authorization submission for Farxiga in Indiana includes the following: confirmed diagnosis with ICD-10 code (E11.9 for type 2 diabetes, I50.22 for chronic systolic heart failure, or N18.3/N18.4 for CKD stage 3 or 4), documentation of trial and failure or intolerance of at least one preferred SGLT2 inhibitor if one exists on the plan formulary, recent lab values (eGFR, A1c, UACR), prescriber's clinical rationale, and the specific dose requested (5 mg or 10 mg).

The timeline matters. Indiana commercial insurers must respond to a standard PA request within 72 hours under state law. Urgent requests, defined as situations where delay could seriously jeopardize the patient's health, require a response within 24 hours. In practice, most electronic PA platforms (CoverMyMeds, Surescripts) return a decision within 24 to 48 hours for standard requests.

If the PA is denied, Indiana patients have the right to an internal appeal and, if that fails, an external review through the Indiana Department of Insurance. The external review is binding on the insurer. Denials are most commonly issued for lack of step therapy documentation. The fix is simple: ensure the chart includes a note that the patient has tried and failed (or has a contraindication to) the plan's preferred agents.

"Prior authorization adds 3 to 7 days to the time-to-fill for SGLT2 inhibitors in most states. Clinicians who submit electronically and include all required documentation on the first attempt cut that window roughly in half." This aligns with findings from the 2023 AMA Prior Authorization Physician Survey 4.

Pharmacy Options: Retail, Mail-Order, and 503A Compounding

Indiana patients filling a Farxiga prescription have three pharmacy pathways, each with different cost and convenience profiles.

Retail pharmacies are the most common route. CVS, Walgreens, Kroger, and independent pharmacies across Indiana stock brand-name Farxiga. The retail cash price for a 30-day supply of dapagliflozin 10 mg tablets sits between $550 and $620 without insurance. With a commercial plan and completed PA, copays range from $0 (with the AstraZeneca savings card) to $75 per month depending on the plan's specialty tier.

Mail-order pharmacy offers convenience and sometimes lower copays. Indiana-based plans affiliated with Express Scripts, CVS Caremark, or OptumRx often provide a 90-day supply for the price of two copays. Patients who plan to stay on Farxiga long-term (and most do, given the chronic nature of its indications) can save 20% to 33% annually by switching to mail-order after the first retail fill.

503A compounding pharmacies in Indiana are licensed by the Indiana Board of Pharmacy and can prepare dapagliflozin formulations when a prescriber writes a patient-specific prescription. This pathway is less common for Farxiga because the commercial tablet is widely available, but it becomes relevant when a patient needs an alternative dosage form (such as a liquid suspension for patients who cannot swallow tablets) or when supply-chain disruptions affect the brand product. Indiana 503A pharmacies can ship compounded medications directly to the patient's address within the state.

Note: 503B outsourcing facilities operate under different federal rules and are not patient-specific. Indiana patients should confirm their compounding pharmacy holds a valid 503A license from the Indiana Board of Pharmacy.

Who Can Prescribe Farxiga in Indiana

Indiana law permits physicians (MD and DO), nurse practitioners, and physician assistants to prescribe dapagliflozin. The scope varies slightly by credential.

Physicians hold full, independent prescriptive authority for all non-controlled and controlled medications. An endocrinologist, cardiologist, nephrologist, or primary care physician can prescribe Farxiga without any supervisory requirement.

Nurse practitioners in Indiana gained full practice authority under Senate Enrolled Act 229, effective July 1, 2024, after completing a transition-to-practice period. NPs who have met this requirement can prescribe Farxiga independently. Those still in their transition period operate under a collaborative practice agreement and can prescribe Farxiga within that agreement's scope 5.

Physician assistants prescribe under a supervisory agreement with a physician. The agreement must explicitly include authority to prescribe legend drugs (non-controlled prescription medications). Farxiga falls within this category.

For telehealth encounters, the prescriber's license type does not change the patient's experience. The prescription is transmitted electronically to the patient's chosen Indiana pharmacy regardless of whether an MD, NP, or PA wrote it.

Transferring a Farxiga Prescription to an Indiana Pharmacy

Patients moving to Indiana or switching pharmacies within the state can transfer an existing Farxiga prescription without a new office visit in most cases.

Indiana Board of Pharmacy rules permit the transfer of non-controlled prescription medications between pharmacies. The receiving pharmacist contacts the originating pharmacy, verifies the prescription details, and processes the transfer. This takes 15 to 60 minutes during business hours. Electronic prescriptions stored in a shared pharmacy network (such as the CVS or Walgreens national systems) can be transferred almost instantly.

One catch applies to out-of-state transfers. If the original prescription was written by a prescriber not licensed in Indiana, the Indiana pharmacy can still fill it as long as the prescriber holds a valid, active license in their home state. However, refills on that prescription may be limited. Patients relocating permanently to Indiana should establish care with an Indiana-licensed prescriber to ensure uninterrupted refills.

The DAPA-CKD trial (N=4,304) showed that dapagliflozin reduced the composite endpoint of sustained decline in eGFR by 50% or more, end-stage kidney disease, or death from renal or cardiovascular causes by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) 6. Patients transferring prescriptions often have an established renal or cardiac indication. Continuity of therapy matters because interruptions in SGLT2 inhibitor use may reverse the hemodynamic benefits that accrue over the first 2 to 4 weeks of treatment.

Cost-Reduction Strategies Specific to Indiana

Indiana patients paying out of pocket or facing high copays have several concrete options beyond standard insurance.

The AstraZeneca Farxiga Savings Card covers up to $150 per 30-day fill for commercially insured patients, effectively making the copay $0 for most plans. The card is not valid for patients on Medicare Part D, Medicaid, TRICARE, or any other federal program. Enrollment takes 2 minutes on the manufacturer's website and the card can be used immediately at the pharmacy.

For uninsured patients, AZ&Me (AstraZeneca's patient assistance program) provides Farxiga at no cost. Eligibility requires a household income at or below 400% FPL ($62,400 for a single individual in 2026). The application requires a signed prescriber certification, proof of income, and a valid prescription. Approval typically takes 4 to 6 weeks, and medication ships directly to the patient or prescriber's office.

Indiana's 211 helpline (dial 2-1-1) connects patients with local prescription assistance programs and charitable care funds. Several Indiana health systems, including IU Health, Franciscan Health, and Parkview Health, operate financial assistance programs that can offset specialty medication costs for qualifying patients.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap under Medicare Part D (effective 2025) benefits Indiana Medicare enrollees who use Farxiga. Patients who previously hit the coverage gap ("donut hole") at around $5,030 in total drug costs now face a hard ceiling of $2,000 in annual out-of-pocket spending, making Farxiga more accessible for the 65-and-older population 7.

Timeline: From First Visit to First Dose

Indiana patients should expect 3 to 10 business days from initial consultation to first dose, depending on three variables: lab turnaround, prior authorization, and pharmacy fulfillment.

Day 1 is the telehealth or in-person visit. If labs are already current (within 90 days), the prescriber can submit the prescription and PA on the same day. If labs are needed, add 1 to 3 days for the draw and result posting.

Days 2 through 5 cover the prior authorization window. Electronic submissions through CoverMyMeds average 1 to 2 business days for approval when documentation is complete. Paper fax submissions take longer. Denial plus appeal can extend this to 10 to 14 days.

Days 3 through 7 cover pharmacy dispensing. Retail pharmacies that stock Farxiga can fill same-day once the PA clears. Mail-order pharmacies add 3 to 5 shipping days. 503A compounding pharmacies may need 5 to 7 business days to prepare and ship a custom formulation.

The fastest realistic path: existing labs, electronic PA approval in 24 hours, retail pickup same day. Total: 2 days. The slowest common path: new labs needed, PA denial requiring appeal, mail-order fulfillment. Total: 14 to 21 days.